Treatment(s) already received-Biological therapy Posts on Medivizor
Navigation Menu

Treatment(s) already received-Biological therapy Posts on Medivizor

Effects of nilotinib on height and safety in children with chronic myeloid leukemia.

Effects of nilotinib on height and safety in children with chronic myeloid leukemia.

Posted by on Aug 29, 2021 in Leukemia | 0 comments

In a nutshell This study assessed the safety and impact on the growth of nilotinib (Tasigna) in children with chronic myeloid leukemia (CML). The data indicated reduced growth rates with nilotinib treatment in children with CML. Some background Chronic myeloid leukemia (CML) is rare in children. However, it affects younger patients more...

Read More

Comparing the safety and effectiveness of pyrotinib versus trastuzumab etamsine for the treatment of HER2-positive metastatic breast cancer.

Comparing the safety and effectiveness of pyrotinib versus trastuzumab etamsine for the treatment of HER2-positive metastatic breast cancer.

Posted by on Jul 11, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the safety and effectiveness between pyrotinib (SHR-1258) and trastuzumab emtansine (T-DM1; Kadcyla) in patients with HER2+ metastatic breast cancer (BC) after previous treatment with trastuzumab (Herceptin) and chemotherapy. The data showed that pyrotinib may be more effective than T-DM1 for these patients. Some...

Read More

Comparing the safety and effectiveness of pyrotinib versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer

Comparing the safety and effectiveness of pyrotinib versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer

Posted by on Apr 18, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the safety and effectiveness of pyrotinib (SHR-1258) plus capecitabine (Xeloda) versus lapatinib (Tyverb) plus capecitabine in patients with metastatic human epidermal growth factor (HER2)-positive breast cancer (BC) after previous treatment with trastuzumab (Herceptin) and chemotherapy. The data...

Read More

Ending trastuzumab treatment in patients with HER2-positive metastatic breast cancer who are in radiological complete remission

Posted by on Oct 20, 2019 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate the effect of stopping trastuzumab treatment in patients with HER2-positive metastatic breast cancer with radiological complete remission.   This study concluded that trastuzumab may be safely stopped in selected patients with radiological complete...

Read More

Searching for patients with chronic myeloid leukemia to try a new combination of targeted treatments.

Posted by on Jun 29, 2019 in Leukemia | 0 comments

In a nutshell This study is searching for patients with chronic myeloid leukemia (CML) to try a new drug ruxolitinib (NSC-752295) with BCR-ABL Tyrosine Kinase Inhibitors. The main outcome that will be measured is the rate of significant reduction of the BCR-ABL marker. This trial is recruiting across the United States. The details BCR-ABL is a protein...

Read More

Managing side effects of ibrutinib treatment

Posted by on Jun 23, 2019 in Leukemia | 0 comments

In a nutshell This study summarised the side effects of ibrutinib (Imbruvica) and how to manage them.  Some background Ibrutinib is an FDA approved drug used to treat lymphoma and leukemia. It works on the immune cells in the body which may lead to many side effects. These include diarrhea, upper respiratory infections, bleeding, tiredness,...

Read More

Searching for patients with advanced non-small cell lung cancer to test a new T-cell treatment

Posted by on May 26, 2019 in Lung cancer | 0 comments

In a nutshell This phase 2 trial will investigate the effectiveness of genetically-engineered cell treatment (GECT) in advanced cancer.  The main outcome will be the response to treatment. This trial is recruiting at the National Cancer Institute, Maryland, US.  The details There are limited treatment options for advanced cancer. One...

Read More

Looking for patients with non-small cell lung cancer to test a new immunotherapy combination

Posted by on May 26, 2019 in Lung cancer | 0 comments

In a nutshell This phase 2 trial will investigate the safety and effectiveness of different treatment combinations containing durvalumab (Imfinzi) in non-small cell lung cancer (NSCLC). The main outcome will be the objective response rate (ORR). The details Non-small cell lung cancer (NSCLC) is a common form of lung cancer. It is often diagnosed at...

Read More

Looking for patients advanced colorectal cancer to test a new treatment and a predictive blood test

Posted by on Apr 17, 2019 in Colorectal cancer | 0 comments

In a nutshell This trial is examining the effectiveness of circulating cell-free tumor DNA (cCFTD) as a predictive factor for the treatment of advanced colorectal cancer with regorafenib (Stivarga) or TAS-102. The main outcome to be measured will be to evaluate the ability of early change of cCFTD after the start of the treatment. This trial will be...

Read More